Tolemy Bio Raises €1.4M Funding To Advance AI-Powered Cell Biology Platform

The investment round was led by Norrsken Evolve, alongside backing from Big Sur Ventures, JME Ventures, Masia, and a newly established UK stealth fund.

Established by Alex Ward and Caelan Anderson, the company is building Orbit, a platform aimed at helping scientists better analyse, interpret, and optimise living cells used in advanced therapies and drug discovery.

Tolemy Bio is addressing a persistent issue in biopharma and cell biology, where research involving living cells still depends on fragmented and highly manual workflows. Critical experimental data is often dispersed across spreadsheets, laboratory instruments, notebooks and disconnected software systems, making it difficult for research teams to effectively leverage AI in drug development and manufacturing.

Read Also - Dessn Raises €5M To Simplify Product Design And Prototyping In Real Codebases

Orbit seeks to solve this by unifying laboratory workflows within a single AI-native platform. The system integrates existing lab tools and data streams while incorporating virtual cell models and AI driven research agents that assist scientists in understanding cellular behaviour and improving experimental decision-making.

Ward said the company was founded to tackle the ongoing challenges researchers face when trying to interpret and reproduce complex cell biology experiments.

Tolemy Bio plans to use the newly secured funding to strengthen its data generation, machine learning, and engineering teams, while continuing to enhance the development of Orbit and support initial customer and partner rollouts. Although the company is headquartered in Cambridge, it said a significant portion of its operations will remain based in Barcelona.

The company’s broader ambition is to create a virtual-cell platform that enables biopharma organisations to move away from traditional trial-and-error research methods and adopt more accurate, data-driven strategies for understanding and controlling living cells.

Alex Ward, co-founder and CEO of Tolemy Bio, said the company was founded to address the difficulties researchers face in interpreting and reproducing complex cell biology experiments.

Our platform, Orbit, is designed to connect experimental data with AI models,” said Ward. “Our goal is to make complex cell biology easier to interpret, optimise, and apply to real therapeutic development.